Monocytes and macrophages in abdominal aortic aneurysm. by Raffort, Juliette et al.
 1
 
Monocytes and macrophages in abdominal aortic aneurysm 
 
Juliette Raffort 1, 2, 3, 4, Fabien Lareyre 1, 4, 5, Marc Clément 1, Réda Hassen-Khodja 4 ,5, Giulia 
Chinetti 3, 4, Ziad Mallat 1, 2 
 
1 Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, 
Cambridge, UK, CB20 SZ. 
2 Institut National de la Santé et de la Recherche Médicale (Inserm), Unit 970, Paris 
Cardiovascular Research Center, 75015 Paris, France 
3 Clinical Chemistry Laboratory, University Hospital of Nice, France 
4 Université Côte d’Azur, CHU, CNRS, Inserm, IRCAN, France 
5 Department of Vascular Surgery, University Hospital of Nice, France 
 
Correspondence should be addressed to: Ziad Mallat, MD, PhD, at Division of Cardiovascular 
Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 2QQ, UK. E-
Mail: zm255@medchl.cam.ac.uk. 
 
Abstract word count: 184 





Abdominal aortic aneurysm (AAA) is a life threatening disease associated with high 
morbidity and high rates of mortality in case of aortic rupture. Major advances in surgical 
treatment have been achieved during the past few years. However, drug-based therapies are 
still lacking, highlighting a real need for better understanding of the cellular and molecular 
mechanisms involved in AAA formation and progression. Main pathological features of AAA 
include extracellular matrix remodeling associated with degeneration and loss of smooth 
muscle cells, as well as inflammatory cell accumulation and activation. The inflammatory 
process plays a crucial role in the disease and substantially impacts many determinants of 
aortic wall remodeling. Here, we focus on the implication of monocytes and macrophages, 
and summarize the current knowledge regarding their roles, origins and functions in AAA 
development and complications. We show and propose that distinct monocyte/macrophage 
subsets play critical differential roles in the initiation, propagation, and healing of the 
aneurysmal process. Based on experimental and clinical studies, we review potential 
translational applications to detect, assess and image the various subsets of macrophages in 
AAA, and discuss their relevance for clinical practice. 
 
Key points 
- Most of the macrophages that accumulate in the aneurysmal aortic wall originate from 
circulating monocytes, mobilized from the bone marrow and the spleen. Some AAA 
macrophages may originate from aortic tissue resident macrophages. 
- Main factors involved in macrophage accumulation in AAA include chemokines/cytokines 
produced in response to tissue injury, products of extracellular matrix degradation, and 
microenvironmental conditions (blood flow, thrombus, periaortic fat, etc.). 
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- Monocytes and macrophages display distinct phenotypes during the development and 
progression of AAA, with major implications for their activation and biological functions. 
- Macrophages exert both pathogenic and reparative roles in AAA through their involvement 
in extracellular matrix remodeling, the promotion and resolution of inflammation, and various 
aspects of the tissue healing response. 
- State-of-the-art translational applications are available, and can be improved and harnessed 
for the use of monocytes and macrophages as diagnostic and prognostic biomarkers, but also 
as therapeutic targets in AAA. 
 
Abbreviations: 
AAA: Abdominal Aortic Aneurysm 
ANGPTL2: Angiopoietin-Like Protein 2 
Apoe-/-: apolipoprotein E-deficient mice 
ASC: Adaptor molecule apoptosis-associated speck like protein containing a caspase 
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CaCl2: Calcium Chloride  
Casp1: Caspase 1 
CCL: CC-chemokine Ligand 
CCR: CC-chemokine Receptor   
CXCR: CXC chemokine Receptor  
CXCL: CXC chemokine Ligand  
CD: Cluster of Differentiation 
CLIO: Cross-Linked Iron Oxide  
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ECM: Extracellular Matrix  
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Aortic aneurysm corresponds to a focal dilatation of the aorta with substantial morbidity and 
mortality, as a result of complications such as aortic rupture 1. Although a remarkable 
progress has been achieved in both open and endovascular surgery, curative pharmacological 
treatments are still lacking 2, underlining a real need to improve our knowledge of the 
mechanisms involved in disease development and progression. While vessel dilatation can 
occur in the abdominal or thoracic aorta, the location of the most common form of aneurysm 
in humans is the infra-renal region of the abdominal aorta, and is the subject of the present 
review.  
Detailed pathological and imaging studies of human abdominal aortic aneurysm (AAA), 
associated with the development of several animal models of the disease have led to the 
characterization of the main mechanisms underlying disease development and complications 
3,4. Pathological features include extracellular matrix (ECM) degradation and loss of vascular 
smooth muscle cells (VSMCs), associated with adventitial and medial inflammatory cell 
infiltration, contributing to vascular remodeling and weakening of the aortic wall. Innate and 
adaptive immune cells including neutrophils, macrophages, mast cells, natural killer cells, 
dendritic cells, B and T cells have been identified in the aortic wall during aneurysm, and 
shown to contribute to its development 5. In this review we focus on the characterization of 
monocytes and macrophages in aortic aneurysm given their critical and distinct roles in 
several steps of the vascular response to injury, and we summarize the current knowledge on 
their origins and roles in disease development and complications. In the limelight of human 
and animal studies, we discuss potential translational applications. 
 
Circulating monocytes and AAA 
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Circulating blood monocytes originate from the bone marrow and correspond to a 
heterogeneous leukocyte population with various subsets differing in terms of morphology, 
cell surface markers, gene expression and functions.  
In humans, 3 main subsets can be distinguished based on the expression of the cell surface 
markers CD14 and CD16. Classical monocytes, defined by high CD14 expression but no 
CD16 (CD14++ CD16-), usually represent up to 90% of the blood monocytes 6,7. They express 
high levels of chemokine receptor 2 (CCR2) and CD62L but low levels of CX3CR1 and are 
characterized by a high expression of genes coding for antimicrobial and phagocytosis related 
proteins, underlining their major role in innate immune responses 7,8. Besides, they express 
genes involved in angiogenesis, wound healing and coagulation, suggesting a potential role in 
tissue repair 9. In contrast, non-classical monocytes are characterized by low level of CD14 
but high CD16 expression (CD14+ CD16++), and display low levels of CCR2 with high levels 
of CX3CR1 6-8. Due to their vascular patrolling properties, they are involved in innate 
immune surveillance of tissues 7,8. An intermediate phenotype characterized by high level of 
CD14 with low CD16 (CD14++ CD16+) has also been described and display pro-inflammatory 
and phagocytic properties 6-8.  
In mice, monocyte subsets express CD11b and CD115 but low levels of F4/80, and are 
classified according to the expression of Ly6C into 2 major subsets that are close to the major 
human subsets in terms of chemokine receptor expression and function 10,11. Ly6C high 
(Ly6Chi) monocytes are considered to be the counterpart of the classical human monocytes 
and are thought to promote inflammatory responses. In contrast, Ly6C low (Ly6Clo) 
monocytes display similar functions as non-classical human monocytes and are involved in 
patrolling, immune surveillance and tissue repair 8,10,11. 
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Monocytosis (increased number of circulating monocytes) has been associated with a number 
of cardiovascular diseases including atherosclerosis and myocardial infarction 7,8,12,13. In 
aortic aneurysm, clinical studies revealed significant modifications of peripheral blood 
monocytes, suggesting their involvement in the disease. A higher proportion of circulating 
intermediate CD14++CD16+ monocytes, concomitantly with a decrease of classical 
CD14++CD16- monocytes levels was observed in patients with AAA compared to healthy 
controls 14,15. Less consistent results were found for CD14+CD16+ monocytes; one study 
identified an increase of this subset in AAA patients compared to controls, whereas another 
study could not find any significant difference 14,15. Other investigators performed proteomic 
and transcriptomic analyses on macrophages derived from human peripheral blood 
monocytes, and revealed differences in protein and gene expression profiles between 
monocyte-derived macrophages of patients with AAA and patients with peripheral arterial 
disease 16. Among the differentially expressed mRNAs and proteins, some were gene products 
involved in pathophysiological mechanisms relevant to AAA such as ECM remodeling or 
inflammation, suggesting a specific role of blood monocyte-derived macrophages in AAA 
pathogenesis. 
To gain further insight into the pathological significance of circulating monocytes in AAA, 
investigators studied their variation in animal models of AAA.  
Several experimental models have been developed, each of them reproduces some of the main 
features of human AAA 17. Schematically, non-dissecting AAA can be created mainly 
through local perfusion/application of porcine pancreatic elastase or calcium chloride, and 
lead to aortic dilation in association with ECM degradation and induction of an inflammatory 
response 17-19. In contrast, dissecting AAA models, as those induced by angiotensin II 
infusion, are characterized by the induction of medial dissection and are also associated with 
ECM degradation and vascular inflammation. The angiotensin II infusion model has been 
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developed in different strains including apolipoprotein E-deficient (Apoe-/-), low density 
lipoprotein receptor deficient (Ldlr-/-) or in some cases C57BL/6 mice, and usually induces a 
dissecting AAA located to the suprarenal aorta, but can also lead to thoracic aortic rupture 
17,20-23.  
An increase of circulating monocytes expressing CCR2 was observed in Apoe-/- mice infused 
with angiotensin II for 14 days 24. Given the ability of CCR2+ monocytes to migrate to sites of 
injury and inflamed tissues 25, their increase in the blood after angiotensin II infusion suggests 
that they could contribute to the vascular inflammatory response. Another study reported 
higher levels of circulating Ly6Chi monocytes and Ly6Clo monocytes, at respectively day 3 
and day 7, in mice that later developed AAA (after 28 days of angiotensin II infusion) 
compared to mice that did not develop AAA 26. Remarkably, monocyte levels did not increase 
and remained stable over time in mice that did not develop AAA after angiotensin II 26. 
Moreover, the efficacy of some treatment strategies (such as administration of recombinant 
angiopoietin-2) in attenuating angiotensin II-induced aortic dilatation and rupture in Apoe-/- 
mice was associated with a reduction of the circulating levels of Ly6Chi inflammatory 
monocytes 27. Interestingly, mice deficient in myeloid differentiation factor 88 (MyD88), a 
critical adaptor protein required for signaling downstream of several toll-like receptors (TLR) 
as well as receptors of the interleukin-1 (IL-1) family of cytokines, showed reduced 
redistribution of monocytes from Ly6Clo to Ly6Chi in both the peripheral blood and spleens 
after angiotensin II infusion, which was associated with a significant attenuation of AAA 
formation 28. The data suggested a pathogenic role of Ly6Chi but a potentially less critical role 
for Ly6Clo monocytes in the development of AAA. However, Nr4a1-/- mice, which are 
deficient in Ly6Clo monocytes 29, displayed increased aortic dilatation and elastin disruption 
in response to angiotensin II 30, potentially suggesting a direct role for Ly6Clo monocytes. 
Nevertheless, the phenotype of Nr4a1 deficient mice could also be due to a role of Nr4a1 in 
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vascular smooth muscle cells 30, or to functional alteration of the remaining Ly6Chi monocytes 
and bone marrow-derived macrophages in the absence of Nr4a1 31,32. The latter hypothesis 
can potentially be addressed by use of mice deleted for an Nr4a1 super-enhancer subdomain 
that differentially controls and decouples Ly6Clo monocyte development from the regulation 
of gene expression in macrophages 33. 
Taken together, these results point to a potentially interesting role of circulating monocytes in 
regulating vascular inflammation and remodeling during the development of AAA, and 
suggest that determination or modulation of their numbers in the blood may be of predictive 
or therapeutic value (see below). Interestingly, a recent study reported the identification of a 
novel atypical monocyte subset (CD11b+ Ly6C- Ceacam1+ Msr1+), called segregated-nucleus-
containing atypical monocytes (SatM), derived from a Ly6C- FcεRI+ SatM progenitor 
downstream of granulocyte/macrophage progenitors. SatM share granulocyte characteristics, 
require CCAAT/enhancer binding protein (C/EBPβ) for their differentiation, and play a 
critical role in fibrosis 34. We suspect that they have a human equivalent and may play 
interesting roles in tissue repair during AAA. Hence, monocytes are composed of multiple 
subsets whose various and distinct functions would be worth of detailed investigation in the 
context of AAA.  
 
Macrophage characterization in AAA  
Over the past decades, several phenotypes of macrophages have been described in inflamed 
tissues, with a particular focus on the dichotomy between “classically activated” M1 and 
“alternatively activated” M2 macrophages 35-37. M1 macrophages are considered to be pro-
inflammatory and characterized by the production of proteolytic enzymes and pro-
inflammatory cytokines such as TNF, IL6, IL12, IL1β, NOS2 or CCL2 5,35. In contrast, M2 
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macrophages play anti-inflammatory roles through the secretion of factors such as IL10 or 
TGFβ, and are involved in matrix remodeling and tissue repair 35. Recently, a specific 
pathway has been described for the generation of NOS2+ macrophages from a subset of 
Ly6Chi monocytes, indicating that specific subsets of monocytes may be endowed with the 
ability to generate functionally distinct macrophage subsets 38. However, while the 
classification between macrophage subsets is well defined in vitro, their distinction in vivo is 
less obvious and more problematic given that selective M1 and M2 stimuli do not occur 
separately in vivo, and markers used to differentiate between the various macrophage subsets 
lack specificity 35,39. Hence, macrophage subsets in vivo rather correspond to a spectrum of 
activation and are characterized by a combination of markers 35. 
Several studies reported the presence of macrophages in the aneurysmal aortic wall both in 
human aortic sections 40 and in animal models of AAA 20,22,41-44. Macrophages accumulate in 
the 3 layers of the aneurysmal aorta but display predominant accumulation in the adventitia 
and the intraluminal thrombus 45,46. To gain further insight into the accumulation of 
macrophages in different aortic layers, Dutertre et al. analyzed the composition of human 
aneurysmal tissues by flow cytometry after separation of the media from the adventitia 45. In 
that study, M2 macrophages were defined as CD15- CD14hi cells which strongly expressed 
the M2 markers CD163 (a high affinity scavenger receptor for the hemoglobin-haptoglobin 
complex), CD206 (mannose receptor) and MerTK (tyrosine kinase receptor involved in 
efferocytosis of apoptotic cells); whereas M1 macrophages corresponded to CD15+ CD14lo 
cells and did not express CD163, CD206, or MerTK. The authors revealed a decrease of M1 
in favor of M2 macrophages in the adventitia of aneurysmal tissue as compared to controls 45. 
Another study on human aortic aneurysmal sections identified M1 macrophages as CD68+ 
CD206- cells and M2 macrophages as CD68+ CD206+ cells 47. The authors also found a 
higher cellular density for M2 in the aortic wall. However, they reported a preferential 
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localization of the M1 subset in the adventitia, while M2 macrophages were predominant in 
the intraluminal thrombus. Isolation of each macrophage subset by laser capture 
microdissection further revealed that gene and protein expression of peroxiredoxin-1 (PRDX-
1), involved in redox status, was higher in M1 compared to M2 macrophages. These results 
are discordant with the findings of Dutertre et al. and could be explained by differences in the 
methods and markers used to identify M1 and M2 macrophages. Besides, it is possible that 
the samples represented different stages of the disease, and that macrophage infiltration and 
polarization evolve during the various steps of aneurysm development and complications. 
Both studies however suggest potentially distinct roles of macrophage subsets in disease 
development and aortic remodeling. 
In that context, macrophage polarization was also studied in animal models of AAA. 
Increased accumulation of total macrophages with a higher M1/M2 ratio was observed in the 
suprarenal aorta of Apoe-/- mice after 7 to 10 days of angiotensin II infusion, and was 
maintained over the 28 days of the experiment 48. The reasons for this M1 shift are not fully 
understood. However, a few pathways were suggested to play a role, including upregulation 
of TLR4 by angiotensin II 48, and a role for ECM remodeling and elastin degradation 
products, particularly VGVAPG repeat sequence 49. Other investigators addressed the status 
and implications of macrophage polarization after prolonged angiotensin II infusion in Apoe-/- 
mice 50. Compared to mice infused with angiotensin II for 28 days, prolonged infusion for 
additional 56 days led to increased aneurysm expansion and propensity to rupture with an 
increase of CD68 positive cells. Immunostaining for CD206 (a marker of M2) was more 
common than NOS2 (a marker of M1-like) in these tissues suggesting that end stage 
aneurysm could be associated with a shift toward M2 polarization. Given their role in tissue 
repair and wound healing, we can hypothesize that the shift toward M2 macrophages may 
result from a compensatory effect, aiming to prevent AAA expansion and rupture. The 
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mechanisms behind such a polarization are not well understood. Intriguingly, although 
angiotensin II promotes the infiltration of Ly6Chi monocytes in the aortic wall, it may also 
directly limit the development of M1 type macrophages, and promote an M2 phenotype 51. 
Besides angiotensin II, factor XIIIa transglutaminase has been identified to play an important 
role in mediating gene expression during M2 polarization 52 and is induced in adventitial 
CXCR3+ macrophages in response to impairment of blood flow 53,54. Macrophages with the 
latter phenotype accumulate in the aneurysmal aortic wall 54. It is tempting to hypothesize that 
reduction of shear stress in advanced aortic aneurysms due to profound alterations of aortic 
wall geometry and hemodynamics may promote that pathway in adventitial macrophages in 
an attempt to limit expansive wall remodeling. Other mechanisms of M2-like polarization 
may involve pathways related to apoptotic cell efferocytosis 55, or clearance of red blood cells 
after hemorrhage. Indeed, hemorrhage associated macrophages including HA-mac, M(Hb), 
and Mhem have been identified in areas of intraplaque hemorrhage and play roles in 
hemoglobin clearance and tissue remodeling 37,56. These macrophages are characterized by the 
expression of CD163, which is involved in hemogloblin-heme uptake and endocytosis of 
haemoglobin-haptoglobin complexes, and their activation leads to the induction of an anti-
inflammatory macrophage phenotype 57,58. CD163 expression is increased in human 
aneurysmal walls as compared with healthy aorta and is mainly found in areas rich in 
hemosiderin adjacent to neoangiogenic microvessels in the adventitia 15. Thus, similarly to 
M2 macrophages, anti-inflammatory HA-mac macrophage subsets characterized by high 
levels of CD163 and low levels of HLA-DR also accumulate in the adventitial layer of AAA 
15,45. 
In summary, based on the results of current studies in mice and humans, we can hypothesize 
that early stages of AAA are associated with a predominant infiltration of macrophages whose 
characteristics are close to the M1 phenotype and probably enhance vascular inflammation. 
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We suspect that some, like NOS2+ macrophages, may directly derive from a selective subset 
of Ly6Chi monocytes 38. This could contribute to increased aortic dilatation and adverse 
vascular remodeling (see below). When the disease evolves, several changes in the artery wall 
such as altered hemodynamics, distinct chemokine/cytokine expression profile, intra-luminal 
thrombus formation, or the occurrence of micro-dissections may lead to the recruitment of 
distinct subsets of monocytes with reparative potential, like Ly6Clo or SatM monocytes, or 
may impact macrophage polarization and promote anti-inflammatory and pro-resolving 
macrophage phenotypes in an attempt to heal the aortic wall and maintain vascular integrity.   
 
Origin of macrophages in the AAA wall 
For decades, it has been assumed that tissue macrophages originate from bone marrow–
derived circulating blood monocytes that extravasate into tissues 59,60. However, recent 
advances in macrophage ontogeny have substantially revisited and refined that concept. At 
steady state, the majority of tissue resident macrophages is self-maintained during adulthood, 
independently of bone marrow progenitors, and originate from embryonic progenitor cells 
that have migrated into these tissues during the embryonic and fetal life 59,60. This is also the 
case for cardiac 61 and vascular-associated resident macrophages 62. Local proliferation of 
tissue macrophages is involved in several cardiovascular processes 63,64, and a greater 
proliferation index has been reported in macrophages of aneurysmal aortas compared to 
controls 45. However, proliferation can occur in both tissue-resident macrophages and those 
derived from circulating monocytes after their infiltration into injured vessels 65. Thus, 
whether vascular-resident macrophages contribute any significant role to aortic remodeling 
during aneurysm development is still unclear (Figure 1).  
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Most of the available evidence, derived in part from bone marrow transplantation 
experiments, points to an important contribution of monocyte-derived macrophages to 
macrophage accumulation in AAA. The use of green fluorescent protein positive bone 
marrow showed that a proportion of macrophages that infiltrated the adventitial layers 
originated from bone marrow monocytes recruited in response to increased expression of 
CXCL12 in the aorta during aneurysm formation after local application of calcium chloride 
(CaCl2) 66. Experiments in Apoe-/- mice infused with angiotensin II also indicate that most of 
the aneurysmal wall macrophages derive from circulating monocytes 26. Interestingly, 
angiotensin II infusion leads to an increase of blood Ly6Chi monocytes at day 3, in parallel to 
their decrease in the spleen with no significant change in the bone marrow, suggesting that 
monocytes/macrophages that accumulate in the abdominal aorta may be mobilized from the 
spleen by angiotensin II. This hypothesis is corroborated by the fact that splenectomy in Apoe-
/- mice infused with angiotensin II induces a decrease of aortic macrophage accumulation 26,67. 
Investigation of the mechanisms involved in monocyte mobilization from the spleen revealed 
that the process did not result from a direct mechanical contraction of the spleen in response 
to angiotensin II, and that splenic B lymphocytes were required for monocyte mobilization 26. 
These results show that monocyte/macrophage mobilization from peripheral reservoirs is an 
important and complex mechanism that contributes to aortic inflammation, and merits further 
investigations into its molecular mechanisms. 
Consistent with the importance of circulating monocytes in the pathogenesis of AAA, their 
depletion in mice using clodronate containing liposomes substantially limits macrophage 
accumulation in the aortic wall and reduces the development and severity of AAA 26,68,69. 
Intriguingly, genetic ablation of monocytes/macrophages in Csf1-/- mice did not prevent AAA 
formation in Apoe-/- mice, and unexpectedly induced intra-mural hemorrhage in the thoracic 
aortas under both Apoe-/- and Apoe+/+ backgrounds 70. Those results should be interpreted with 
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caution given the low number of Csf1-/- mice used in that study and the unusually low 
percentage of angiotensin II-induced AAA in the Csf1+/+ controls 70. However, an important 
difference between clodronate depletion and Csf1-/- mice is that clodronate only depletes 
circulating monocytes without affecting vascular-associated resident macrophages of the 
adventitia, whereas Csf1-/- are also deficient in arterial resident macrophages 62. It is thus 
tempting to hypothesize that the latter play essential roles in preserving vascular integrity.  
 
Monocyte recruitment to the AAA wall 
The importance of monocyte mobilization from peripheral organs led to the study of the 
mechanisms responsible for their mobilization and recruitment into the injured aortic wall. 
Given that 3 major chemokine/chemokine receptor pathways (CCL2/CCR2, 
CX3CL1/CX3CR1 and CCL5/CCR5) control the recruitment of circulating Ly6Chi and 
Ly6Clo monocyte subsets in atherosclerosis 71, those pathways were the most studied in the 
context of AAA. 
CCL2 expression and secretion from aortic explants is increased in response to angiotensin II 
infusion compared to control mice 40,72. In fact, an amplification loop between CCL2 and IL6 
has been described in the aortic wall following angiotensin II infusion, where IL-6 and CCL2 
production by aortic adventitial fibroblasts initiate monocyte recruitment, which in turn, 
differentiate into macrophages and stimulate the proliferation of aortic adventitial fibroblast, 
leading to additional cytokine/chemokine production in a vicious circle 73. CCR2 global 
knockout or CCR2 specific deficiency in leukocytes decreased aortic dissection and aneurysm 
formation, which was associated with a decreased number of aortic macrophages and an 
inhibitory effect on inflammatory cytokine expression in angiotensin II infused mice 40,72. 
Similarly, CCL2 global knockout as well as CCL2 deficiency in bone marrow derived cells 
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showed protective effects in the model of elastase-induced aneurysm, and was associated with 
a drastic reduction of aortic Mac-2+ (galectin-3) macrophages 74. These results confirm the 
role of Ly6Chi monocytes and of CCL2/CCR2 axis in macrophage accumulation and the 
promotion of vascular inflammation during the development of aortic aneurysm. 
The role of the other chemokine pathways received less attention. Deletion of CX3CR1 led to 
partial protection against fatal aortic dissection in a model of angiotensin II and anti-TGFβ 
infusion 22. Interestingly, CX3CR1 and CCR2 were sequentially and differently expressed in 
the aortic wall during the early stages of AAA development, and this was associated with 
early predominance of Ly6Chi over Ly6Clo monocyte recruitment in the abdominal aorta 26. 
Inhibition of CXCL4/CCL5 heterodimer formation was associated with a reduction of 
monocyte/macrophage infiltration in an elastase-induced aneurysm 75. However, deletion of 
CCR5 did not alter aortic disease in a model of CaCl2-induced AAA 76.  
In addition to monocyte recruitment, chemokines may also modulate macrophage retention 
within the tissue. Regulators of G-Protein Signaling (RGS) proteins target GTPase activity of 
chemokine receptors that are coupled to Gαi subunits, and desensitize receptor signaling 77. 
Interestingly, RGS1 is highly expressed in human AAA tissue compared to non-aneurysmal 
vascular tissue 78. Rgs1 deficient mice showed reduced leukocyte trafficking, increased 
macrophage chemotaxis and lower macrophage retention into the aortic wall, which was 
associated with a protection against aneurysm formation and progression 78. 
In addition to chemokines and cytokines, the selectin family is known for its role in immune 
cell interaction with the vessel wall 79. L-selectin deficiency impaired both neutrophil and 
monocyte/macrophage recruitment and suppressed elastase-induced AAA formation 80. As 
neutrophils were recruited to the aortic wall before macrophages, impaired macrophage 
accumulation could be attributed at least in part to diminished neutrophil recruitment and 
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activation. Indeed, neutrophils are able to promote monocyte recruitment through cytokine 
secretion, neutrophil extracellular trap formation or secretion of granule proteins, thereby 
inducing adhesion and migration of monocytes to the site of inflammation 81. 
What induces chemokines and chemotactic products in the vascular wall during the 
development of AAA? Several risk factors of AAA, including smoking and hypertension, 
have been associated with inflammatory activation of the vascular wall 82,83. Moreover, ECM 
remodeling, changes in hemodynamics and circumferential stress, or the occurrence of micro-
dissections and intra-mural hemorrhage during the progression of AAA may further impact 
inflammatory cell recruitment and activation. Those mechanisms have been addressed in 
several experimental studies. 
Macrophages were observed to accumulate predominantly in regions of medial disruption on 
the adventitial side as indicated by elastin fragmentation, suggesting that ECM components 
could act as chemotactic stimuli 50. In vitro experiments further revealed that soluble proteins 
extracted from human AAA tissue enhanced human U937 monocyte migration in a 
concentration dependent manner 84. The authors attributed the monocyte chemotactic activity 
in the AAA extracts to the presence of elastin degradation products and intact cell surface 
receptors for elastin related ligands 84. Hence, elastin degradation products may promote 
monocyte recruitment in the aneurysmal wall, which in turn will secrete proteolytic enzymes 
that further degrade the tissue. A variety of other molecules associated with ECM remodeling 
including osteopontin, thrombospondin-1, and plasminogen, have also been shown to impact 
monocyte/macrophage recruitment, either directly or indirectly 85-87. ECM degradation may 
lead to microdissections and intra-mural hemorrhage, which could further recruit more 
monocytes/macrophages into the aortic wall. Indeed, increased migration of human 
monocytes was reported in response to hemoglobin and conditioned medium obtained from 
adventitial human AAA 15.  
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Macrophage infiltration can also be modulated by the intraluminal microenvironment, and 
more particularly, by changes in hemodynamic conditions. Macrophage accumulation in the 
elastase-induced aneurysm model was inversely correlated to luminal flow and wall shear 
stress 88. High aortic flow and wall shear stress were associated with increased medial 
macrophage apoptosis. Interestingly, CCL2 mRNA expression in the aorta was inversely 
correlated with the level of blood flow and could partly explain the reduction of macrophage 
accumulation in media of the high flow group. The abluminal microenvironment, such as the 
peri-aortic adipose tissue, may also impact macrophage infiltration. 
 Obesity is associated with AAA 89 and periaortic fat volume correlated with the dimensions 
of both thoracic and abdominal aortas, suggesting that local fat accumulation may contribute 
to aortic remodeling 90. In fact, periaortic adipose explants from abdominal aortas of high fat-
fed mice showed greater CCL2 release and higher capacity to induce migration of peritoneal 
macrophages, compared to mice fed a low fat diet 91.  
Risk factors and changes in the AAA microenvironment may also directly impact the 
activation, adhesive and migratory properties of circulating monocytes. For example, 
thrombomodulin and CD14 expression in monocytes significantly modulate monocyte 
production of inflammatory mediators, adhesion to endothelial cells and monocyte 
chemotaxis, resulting in significant attenuation of macrophage accumulation in the aortic wall 
and significant prevention of AAA development in mice with either total CD14 or LysM-Cre 
restricted thrombomodulin deficiency 92,93. Human studies confirm that circulating monocytes 
of patients with AAA display higher levels of circulating monocytes exhibiting LFA-1 and 
Mac-1, as compared to controls 94. Moreover, blood monocytes from AAA patients exhibit 
higher monocyte adhesion to the endothelial monolayer and higher transmigration ability 
through the endothelium in vitro compared to controls 94.  
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Roles of macrophages in AAA 
ECM degradation 
Macrophage accumulation in the aneurysmal aortic wall plays crucial roles in the response to 
tissue injury. Macrophages may profoundly alter the balance between destructive tissue 
remodeling and reparative tissue healing through their control of extracellular matrix 
remodeling and their roles in both the promotion and resolution of the inflammatory response 
95. 
ECM remodeling results from a balance between the activities of proteases and their 
inhibitors. Increased expression of proteases such as cathepsins or metalloproteinases (MMPs) 
is observed during AAA development, and deficiency in these enzymes has revealed 
protective effects 42,96-98. Conversely, enhanced AAA formation is observed in mice deficient 
in tissue inhibitors of metalloproteinases (TIMPs) 99. The expression of cathepsins, MMPs 
and TIMPs is altered in blood monocyte-derived macrophages from patients with AAA 
compared with patients with peripheral arterial disease, and increased expression of MMPs or 
cathepsins colocalize with macrophages in the aneurysmal wall, suggesting a role for 
monocyte/macrophage-derived proteases in ECM remodeling during aneurysm 16,100,101. This 
is supported by mechanistic studies in animal models of AAA. Mmp9 knockout mice were 
protected against aneurysm formation, and reconstitution with MMP9-competent 
macrophages through bone marrow transplantation or reinfusion of wild type peritoneal 
macrophages, re-established increased susceptibility to aneurysm formation 42,96. Some 
investigators further revealed a differential mRNA and protein expression of MMP9 between 
M1 and M2 macrophages within the aneurysmal wall, suggesting that macrophages may 
differentially regulate ECM degradation depending on their phenotype and activation profile 
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47. Another study identified macrophages positive for osteoclast markers in human 
aneurysmal aortas, and revealed higher protease activity in these cells compared to 
undifferentiated macrophages 102. Inhibition of osteoclastogenic differentiation by 
bisphosphonate treatment in an animal model inhibited aneurysm development, supporting the 
contribution of osteoclast-like macrophages to AAA pathogenesis. Others identified 
previously unsuspected roles for telomerase reverse transcriptase (TERT) in the regulation of 
macrophage proteolytic activity during AAA formation, through the modulation of MMP2 
expression 103. 
Another process related to ECM degradation is macrophage invasiveness and migration 
within the tissue. A recent study showed increased formation of podosomes by macrophages 
infiltrating the aneurysmal wall 104. KLF5 expression in macrophages was increased in the 
context of murine and human AAA, promoted podosome formation and macrophage 
migration through upregulation of mammalian myosin Myo9b and modulation of RhoA 
signaling, and increased the susceptibility to experimental AAA 104. However, whether 
podosome formation per se is required for KFL5-dependent pro-aneurysmal effects in 
macrophages is still unclear.  
 
Inflammatory response 
In addition to ECM remodeling, inflammation is one of the main features of aneurysm 
pathophysiology 105. Macrophages are both producers of and respond to inflammatory 
mediators 106-108. Macrophages infiltrated in the aneurysmal wall have been identified to be a 
major source of the chemokine CXCL1, which attracts and recruits neutrophils that produce 
IL-6 109. As mentioned above, increased IL6 levels during aneurysm formation promote 
monocyte differentiation into activated macrophages that secrete CCL2, which in turn 
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promotes more monocyte recruitment into the aorta 40. Cytokines are key mediators of 
inflammation and important regulators of various immune and non-immune cells in the aortic 
wall. Most of the knowledge on the direct roles of cytokines in AAA comes from studies 
using animals with global rather than monocyte/macrophage selective deficiency in the 
cytokine of interest or in the pathways that leads to their production. This is the case for total 
deletion of each of the components of the canonical inflammasome pathway Nlrp3, Asc, 
Casp1, or I11b 110,111, or for total deletion of Tnf 112or Il6 113, which significantly limit AAA 
development. Conversely, total deletion of Il10, an immunosuppressive cytokine that reduces 
MMP activation and preserves matrix integrity, substantially aggravates AAA formation 114. 
Interestingly, a negative correlation was found between IL6 and IL10 expression in human 
AAA explant cultures, and the balance between these cytokines appears to modulate the 
immune response in the aortic wall 115. 
A better proof of the direct contribution of leukocytes, and more particularly macrophages, to 
the inflammatory process in AAA is exemplified in an animal model with myeloid specific 
deficiency of Krüppel-like factor 6 (KLF6). KLF6 is a transcription factor robustly expressed 
in macrophages 116. Klf6 heterozygous mice as well as mice with myeloid-specific deletion of 
Klf6 manifest a phenotype of exacerbated AAA, with increased infiltration of macrophages 
and increased IL6 expression in the aortic wall 117. The investigators revealed that granulocyte 
macrophage colony-stimulating factor (GM-CSF) is a direct target of KLF6, and its increased 
production by macrophages contributed to AAA development. 
Regulation of macrophage inflammatory activity by a variety of factors other than 
chemokines and cytokines may also alter the development of AAA. Angiopoietin-like protein 
2 (ANGPTL2) is abundantly expressed in both murine and human macrophages infiltrating 
the aneurysmal aortic wall 118. Treatment of macrophages with ANGPTL2 increases the 
expression of pro-inflammatory cytokines and MMP9, suggesting that Angptl2 may regulate 
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macrophage activity in AAA in an autocrine manner. This is supported by decreased 
inflammation and MMP9 expression in macrophages of Angptl2 deficient mice, along with 
reduced AAA development 118. Other mediators of macrophage activity may include 
Peroxisome Proliferator-Activated Receptor (PPAR)-δ, whose activation in macrophages 
attenuated the incidence and severity of AAA in experimental models, concomitantly with a 
decrease of inflammatory mediators such as CCL2 or IL1β 119. 
A recent study identified a major role for NOS2 expression in VSMCs in mediating the 
development of thoracic aortic aneurysms 120. The authors suggested an impact of high levels 
of NOS2 on elastin degradation and potentially VSMC contraction, although the exact 
pathogenic mechanisms are still unclear. NOS2 is highly expressed by a subset of 
macrophages 38 and is found in AAA disease 121. NOS2 inhibition did not affect aortic 
dilatation in a mouse model of elastase infusion 122 but significantly limited AAA formation 
in a more severe elastase-induced model in rats 123,124. Moreover, angiotensin II markedly 
stimulates the accumulation of NOS2+ macrophages in the aorta 125, particularly under 
conditions of reduced TGF-β signaling 69, and NOS2 production by those macrophages 
directly contribute to angiotensin II-induced aortic AAA and dissection, in part through 
enhanced MMP activation and ECM degradation 69. 
 
Tissue healing and repair 
Beside their roles in promoting inflammation and matrix degradation, macrophages are 
important for tissue remodeling during the healing response. Tissue debris and toxic products 
like extracellular hemoglobin 126 accumulate in the aortic wall during AAA and can be 
engulfed by macrophages 47. Macrophage differentiation toward the HA-mac phenotype is 
associated with enhanced hemoglobin uptake and increased anti-inflammatory IL-10 secretion 
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15, pointing to a protective role of macrophages through hemoglobin clearance, regulation of 
the oxidative stress and resolution of the inflammatory response during AAA. 
It is noteworthy that despite their roles in the clearance of toxic products, macrophages are 
capable themselves of generating large amounts of reactive oxygen species. However, the 
impact of oxidative stress on macrophage activity during AAA appears to be more complex 
than initially anticipated. For example, protection of thrombomodulin deficient mice against 
AAA was partly attributed to decreased generation of reactive oxygen species by 
macrophages 93. A major source of reactive oxygen species in macrophages is the NADPH 
oxidase, which is composed of transmembrane and cytosolic subunits including p47phox and 
gp91 (also known as NOX2) 127. p47phox global deficiency decreased incidence of 
angiotensin II-induced AAA and was associated with decreased generation of reactive oxygen 
species as well as reduced aortic macrophage infiltration 128. In contrast, both gp91 global 
deficiency and gp91 specific deletion in bone marrow-derived cells reduced the level of 
reactive oxygen species in AAA lesions but unexpectedly aggravated AAA and promoted M1 
phenotype with enhanced expression of IL1β and MMP9 129. However, a recent study 
suggested a role for gp91 in promoting HMGB1 production by macrophages, which was 
associated with an overactivation of the adaptive Th17 immune response, and aggravation of 
AAA in the experimental mouse model of elastase perfusion 130. Thus, the role of 
macrophage-dependent oxidative stress in AAA will need further investigation. 
To summarize, macrophages display both pathogenic and protective functions in AAA 
pathophysiology through their involvement in ECM remodeling, inflammation and oxidative 
stress (Figure 2). The regulation of these functions is complex and may evolve during the 
different stages of disease development and progression, and is influenced by the local 
microenvironment. In addition to the roles described above, we believe that other interesting 
functions of macrophages would be worth of investigation in relation to AAA pathogenesis. 
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For instance, macrophages are involved in the clearance of apoptotic debris 131. Impaired 
efferocytosis profoundly alters the development and progression of atherosclerosis 132,133 and 
ischemic cardiovascular diseases 134,135, and is probably highly relevant to tissue remodeling 
and repair in the context of AAA. CXCL10-dependent CXCR3+ macrophages that produce 
FXIIIA accumulate in the adventitia of human AAAs 54. We believe that they may contribute 
to matrix cross-linking and limitation of aneurysmal expansion of the aortic wall. CXCR3+ 
macrophages may also co-express CD163 54, suggesting additional roles in hemorrhage 
clearance and induction of an anti-inflammatory environment. Recent findings also revealed 
the contribution of perivascular macrophages to vessel permeability in non-pathological 
conditions 136. Wall thickening occurring during AAA is often associated with the occurrence 
of microdissections, and it is tempting to hypothesize a role for adventitial macrophages in 
regulating vascular permeability during AAA. Finally, a role has been identified for skin 
macrophages in regulating salt-dependent volume retention through VEGF-C-dependent 
regulation of the lymphcapillary network 137. Whether aortic wall macrophages may also play 
such a role is still unknown. We believe that this merits further exploration given the recently 
proposed role of interstitial fluid pressure regulation in the pathogenesis of aortic aneurysm 
and the susceptibility to aortic dissection 138.  
 
Potential translational applications  
Monocytes and macrophages as diagnostic and prognostic biomarkers of AAA 
The mechanistic role of monocytes/macrophages in the development and complications of 
AAA suggested interesting perspectives for translational applications (Figure 3).  
Variations in circulating monocyte subsets during AAA, as well as changes in monocyte 
activation status, 14,16,94 suggest that such parameters could possibly be useful as non-invasive 
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biomarkers. Nevertheless, further studies are required to address the correlation between those 
variations and the characteristics of the aneurysm, such as its morphology, size or risk of 
rupture. Moreover, the specificity of those variations should be explored as the phenotype and 
activation status of circulating blood monocytes may be altered in a wide range of diseases 
including cardiovascular and inflammatory pathologies 7,8,12. 
In addition to their potential use as circulating biomarkers, other experimental studies indicate 
that macrophages could be used as imaging targets. Macrophage activity may be tracked by 
magnetic resonance imaging (MRI) used to detect the phagocytosis of ultrasmall 
superparamagnetic iron oxide (USPIO) contrast agent. The use of this technique in 
experimental models of AAA showed co-localization of these particles with phagocytic cells 
in the adventitia 41, suggesting a potential utility in assessing the impact of macrophage-
dependent processes on the development and progression of AAA in vivo. Nevertheless, 
surrounding tissues, such as the liver, are also able to uptake USPIO and can represent a 
challenge to acquire correct and reliable imaging of the aorta in vivo. Besides, the turnover of 
USPIO in aortic macrophages remains to be determined before a potential use of these 
particles for multiple serial imaging of the inflammatory response during the progression of 
AAA. 
Another targeted approach is PET-CT imaging with fluorine-18-labeled cross-linked iron 
oxide (CLIO) nanoparticles 67. The technique was used in Apoe-/- mice infused with 
angiotensin II, and ex vivo analysis of the aortas by flow cytometry confirmed that 90% of the 
PET signal was due to uptake of nanoparticles by monocytes/macrophages, supporting the 
reliability of the method for macrophage quantification in the aortic wall in vivo. Early PET-
CT imaging revealed that the signal was increased in aneurysms that grew over time, 
compared with aneurysm that did not increase in diameter. As the doses used in experimental 
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models are lower than the approved clinical doses, the results are highly encouraging for 
translational applications.  
18F-fluorodeoxyglucose (18F-FDG) is a marker that accumulates in cells with high metabolic 
activity, which led to consider 18F-FDG as a potential marker of vessel wall inflammation 139. 
However, only a few small clinical studies addressed the usefulness of PET-CT imaging in 
the context of AAA. A review comparing the results of six clinical studies revealed 
heterogeneous results when determining the association between 18F-FDG uptake and AAA 
growth 140. One study investigating USPIO-MRI showed that AAA growth was higher in 
patients with focal USPIO uptake in the aneurysmal wall compared to patients with diffuse or 
no USPIO uptake 141. Another study compared 18F-FDG PET-CT imaging with USPIO-
enhanced MRI in the same cohort of patients 142. While both 18F-FDG PET-CT and USPIO-
MRI uptake detected vascular inflammation in association with AAA, their distribution was 
distinct, 18F-FDG activity being mainly detected in the shoulder region, whereas USPIO 
uptake was more apparent in the main body of the aneurysm. These results suggest that the 
two techniques may be complementary in the characterization of AAAs, 18F-FDG uptake 
reflecting glycolytic activity and potentially M1-like inflammatory pathogenic properties, 
whereas USPIO detection more probably reflects phagocytic activity and may potentially be a 
better indicator of the reparative function of macrophages. Given the complexity of 
macrophage roles in the pathogenesis of AAA, further investigations will be useful to validate 
the use of those techniques to predict AAA progression or risk of rupture before their 
potential use in medical practice. 
In the near future, other imaging tools that better identify macrophages will be available. For 
example, PET tracers such as DOTATATE, which can be labeled using either 68Ga or 64Cu, 
have shown macrophage binding properties thanks to a specific binding affinity for 
somatostatin receptors. Studies in animal models demonstrated the uptake of 68Ga-
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DOTATATE in atherosclerotic plaques 143, and a PET/CT clinical study found an association 
between increased 68Ga-DOTATATE uptake in large arteries and the presence of 
cardiovascular risk factors 144. Interestingly, a PET/MRI study in patients with carotid artery 
plaques revealed correlation between CD163 gene expression and 64Cu-DOTATATE uptake, 
suggesting more selective detection of alternatively activated macrophages by DOTATATE 
145. More recently, PET imaging using 18F-Macroflor, a small-size renally excreted 
polyglucose nanoparticle that displays high affinity for macrophages, was used successfully to 
detect tissue-resident or newly infiltrated macrophages in several experimental models of 
atherosclerosis and myocardial infarction 146. There is currently no published study on the use 
of 64Cu-DOTATATE or 18F-Macroflor to image AAA. We believe that PET/MRI using 
64Cu-DOTATATE or 18F-Macroflor deserves further investigation in this context. 
 
Monocytes and macrophages as therapeutic targets in AAA 
There are several potential possibilities to target monocyte/macrophage recruitment, 
accumulation and activation during the progression of AAA, although most of the approaches 
would suffer a lack of selectivity for the monocyte/macrophage lineage. 
Inhibition of the chemokine axis has shown efficacy in limiting monocyte recruitment in 
animal models of AAA. This was the case after blockade of either CXCR4/CXCL12 or 
CCL2/CCR2 signaling pathways 66,68. With regard to CCL2/CCR2, further studies revealed 
that its specific inhibition in leukocytes or in bone marrow-derived cells was protective 
against aneurysm formation 74,147. In contrast, global CCL2 deficiency or systemic CCL2 
blockade, were respectively less protective or even worsened aneurysm formation 74,147. The 
reasons for those unexpected findings are still unclear. Nevertheless, the data suggest that 
future research should be oriented to test drugs that inhibit CCL2/CCR2 pathway in specific 
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cell subsets in order to optimize therapeutic efficiency and limit adverse effects. For example, 
targeting CCR2 degradation in circulating monocytes using siRNA nanoparticles prevented 
monocyte accumulation at sites of inflammation 148. This treatment has been tested in several 
cardiovascular disease settings including atherosclerosis, myocardial infarction or 
myocarditis, and revealed beneficial effects 148,149. It will be interesting to test the same 
therapeutic strategy in the context of AAA. The protective effect of other drugs on AAA has 
also been linked to modulation of the CCR2 pathway. For example, administration of 
everolimus, an immunosuppressive drug mostly used in drug-eluting stents, protected mice 
against angiotensin II-induced aortic dilatation through a decrease of both bone marrow and 
circulating CCR2 monocytes 24.  
Besides CCL2/CCR2, treatments targeting CCL5/CCR5 may also be useful. Treatment of 
mice with MKEY, an inhibitor of CXCL4/CCL5 heterodimer formation, limited AAA 
enlargement and was associated with a reduction of mural macrophage infiltration and elastin 
degradation 75. MKEY treatment suppressed aortic leukocyte migration without affecting their 
migration into other lymphoid organs such as lymph nodes and spleen. Further investigations 
are required to substantiate the feasibility and safety of the approach. However, these results 
are encouraging for translational applications in AAA. Indeed, some CCR5 antagonists are 
drugs already approved and currently used in medical practice in the setting of HIV infection, 
and several clinical studies using CCL5/CCR5 antagonists have been completed or are still 
ongoing in other disease settings 150. It is noteworthy that the chemokine axis is highly 
redundant. The development of evasins (chemokine-binding proteins) with broad C, CC and 
CXC-binding properties 151 may allow a better and more efficient targeting of 
monocyte/macrophage recruitment in AAA.   
Targeting of cytokines would be less selective for monocytes/macrophages but is worth of 
consideration in translational approaches. Tocilizumab is a humanized monoclonal antibody 
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specific for the IL6 receptor, and has proven efficacy in the treatment of rheumatoid arthritis 
152. IL6 is an important regulator of inflammation and macrophage activation during AAA 40, 
and Mendelian randomization approaches provided strong evidence for the involvement of the 
IL6 receptor pathway in human AAA 153 and human coronary artery disease 154,155. Thus, we 
believe it will be worth testing Tocilizumab or other inhibitors of the IL6 pathway (including 
IL6 transsignaling) in the context of AAA. Blockade of IL1β has shown efficacy in 
experimental models of AAA 111. Intriguingly however, a recent randomized, double-blind, 
placebo-controlled clinical trial using the monoclonal anti-IL1β antibody ACZ885 
(canakinumab) showed lack of efficacy on aneurysmal growth rate in AAA patients (31 
ACZ885 and 33 placebo) with infrarenal AAAs of 40 mm to 50 mm 150. Although the results 
do not exclude the involvement of the IL1 pathway in AAA (IL1 receptor can be activated by 
other ligands than IL1β), and the lack of efficiency of canakinumab should prompt us to 
reconsider our understanding of IL1β in the pathogenesis of AAA. It is interesting to note that 
Mendelian randomization studies did not confirm the causality between the IL1 pathway and 
the occurrence of cardiovascular diseases, including AAA 156. However, the latter study 
addressed the relationship between genetic variants of IL1RN (IL1 receptor antagonist) and 
cardiovascular diseases, and does not allow to draw valid conclusions about the causality of 
the individual IL1α or IL1β cytokines in disease development. Another potential explanation 
of the disappointing clinical results is that anti-IL1β therapy may be useful only in a subset of 
AAA with a high inflammatory burden. Combining state-of-the-art diagnostic approaches to 
detect AAA that harbor an active inflammatory component (see above) with more targeted 
anti-inflammatory therapy may prove useful in improving the management of patients with 
AAA. Another example of such a combinatory diagnostic and therapeutic approach is the 
detection of increased uptake of 18FDG in AAA, indicative of high glycolytic activity, 
followed by the administration of a glycolysis inhibitor to limit macrophage activation 157. 
 31
This treatment has proven to be successful in animal models of AAA 157, and may deserve 
consideration for future translation to the human setting.  
Modulation of macrophage phenotype and activity could represent another therapeutic option. 
Experimentally, intravenous injection of M2 macrophages exhibited protective effect on 
CaCl2-induced aneurysm, as demonstrated by improved survival, decreased aortic dilatation 
and elastin preservation 49. Thus, therapeutic strategies or drugs with known impact on 
macrophage polarization may be of interest. For example, D-series resolvins increase M2 and 
decrease M1 macrophages, and their administration either before or after induction of 
experimental AAA halted disease development and progression 158. Treatment of 
experimental AAA with mesenchymal stem cells reduced pathogenic NOX2 activation in 
macrophages, although the mechanisms remained unclear 130. T regulatory cells control the 
inflammatory response in AAA 114. Several studies revealed that administration of T 
regulatory cells or their endogenous induction by IL2 had protective effects on aneurysm 
development, which were associated with reduced macrophage infiltration in the aorta 159-161. 
In vitro experiments further revealed that T regulatory cells decreased macrophage CCL2 
secretion as well as protease expression and activity, in part through the induction of IL10 160. 
Besides, T regulatory cells downregulated M1- and upregulated M2-associated genes 161, 
making them attractive candidates for the immunotherapy of AAA.  
Finally, while systemic treatments targeting macrophage polarization have provided 
encouraging results, recent advances in the understanding of the impact of biomaterials on 
macrophage phenotype should offer new perspectives 162. Several studies revealed a 
previously unappreciated impact of roughness, size, shape and chemical composition of 
biomaterials on macrophage phenotype. These recent findings could offer new opportunities 
to locally modulate M1/ M2 polarization in order to limit aneurysm expansion. 
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Perspectives for future research 
In the limelight of experimental and clinical studies, future directions for fundamental and 
translational research can be suggested. Even if different subsets of monocytes and 
macrophages have been identified, their distinct origins, roles and functions appear more 
complex than previously anticipated and several points remain to be elucidated. Are specific 
monocyte subsets wired to differentiate into specific macrophage subsets or are they able to 
indifferently differentiate depending on the local micro-environnement? What is the precise 
role in AAA of recently identified subsets such as SatM or tissue resident macrophages? Are 
the various subsets directly representative of the stages of disease development and 
progression? Do they closely correlate with clinical outcomes and could they be used in daily 
practice as diagnostic or prognostic tools, or as therapeutic targets? 
Epidemiological studies have highlighted the association of AAA with risk factors including 
age, male sex, smoking, hypertension or low HDL-cholesterol levels 1. Interestingly, these 
factors may impact on monocyte/ macrophage activity and function 37,163-168. Additional 
research will be required to explore the molecular pathways that could link those risk factors 
with the contribution of monocytes/macrophages to AAA. The development of experimental 
models of AAA over the past decade has offered great opportunities to study the role of 
monocytes/ macrophages in AAA pathogenesis. However, none of those models perfectly 
reproduces the human features of AAA, highlighting a real need to develop new and more 




Several experimental and clinical studies implicate monocytes/macrophages in all stages of 
AAA formation, from initial development to the occurrence of microdissections and rupture 
(Figure 4). In the last decade, we witnessed an impressive advance in our understanding of the 
cellular and molecular mechanisms involved in monocyte mobilization and recruitment to 
sites of vascular injury, and the mechanisms that control macrophage differentiation, 
proliferation, activation and phenotype switch. This knowledge is now backed by the 
development of state-of-the-art imaging techniques to detect and track monocyte/macrophage 
accumulation and activation in vivo, the development of new anti-inflammatory therapies as 
well as additional technological improvements that will allow selective manipulation of 
various macrophage functions in vivo. We truly believe that the combination of such 
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Figure legends 
Figure 1: Origins of macrophages in the aneurysmal aortic wall. 
Most macrophages accumulating in the aneurysmal aortic wall probably derive from 
circulating monocytes, which are produced in the bone marrow and can be mobilized from 
peripheral reservoirs such as the spleen. A contingent of macrophages may also originate 
from tissue resident macrophages developed from embryonic precursors and early post-natal 
circulating monocytes. The diverse origin of macrophages lead to the development of 
macrophage subsets with distinct phenotypes, with major implications for their activation and 
biological functions in AAA development and progression.  
 
Figure 2: Role of macrophages in AAA pathogenesis and the main factors that modulate their 
activities.  
Macrophages accumulating in the aneurysmal aortic wall play crucial roles in AAA 
pathogenesis and complications through their implication in extracellular matrix remodeling, 
the promotion and resolution of inflammation, and various aspects of the tissue healing 
response. In turn, their recruitment, accumulation, proliferation and activation are modulated 
by chemokines/cytokines produced in response to tissue injury, products of extracellular 
matrix degradation, and microenvironmental conditions (blood flow, circumferential stress, 
thrombus, peri-aortic fat, etc.). 
 
Figure 3: Translational approaches. 
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Circulating monocytes and infiltrated macrophages can be used as biomarkers and imaging 
targets, with potential diagnostic and/or prognostic value in medical practice. Various 
potential applications can be envisaged to treat and/or limit AAA growth and complications 
based on modulation of cytokine and chemokine pathways, or modulation of macrophage 
phenotype and activity.  
 
Figure 4: Hypothesized contribution of monocyte and macrophage subsets to AAA 
pathogenesis. 
AAA lesions are characterized by ECM degradation, loss of VSMCs, and immune cell 
infiltration (A). Classical monocytes infiltrate all layers of the vascular wall. Their 
differentiation into several types of macrophages, including M1 macrophages, NOS2+ 
macrophages and osteoclast-like macrophages is associated with enhanced production of pro-
inflammatory mediators and matrix degrading proteases, which weaken the aortic wall and 
promote expansive aortic remodelling. Eventually, this favours microdissections and intra-
mural haemorrhage, neo-angiogenesis and intraluminal thrombus formation, and may further 
enhance immune cell infiltration and activation. If those processes are not contained, they 
may ultimately promote aortic wall rupture.  
(B) The development and progression of AAA may be delayed through compensatory 
mechanisms that limit AAA expansion and maintain vascular integrity. Thanks to their ability 
to secrete anti-inflammatory mediators and pro-fibrotic factors, M2 macrophages may 
contribute to the resolution of inflammation and may promote tissue healing. HA-mac 
macrophages are involved in haemoglobin clearance, exert anti-inflammatory properties and 
regulate oxidative stress, and may contribute to aortic tissue repair. Other macrophage subsets 
such as CXCR3+ macrophages may limit expansive aortic wall remodelling through their 
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production of transglutaminase factor XIIIA. Non-classical monocytes may give rise to M2, 
HA-mac or CXCR3+ macrophages, but all those tissue healing-associated macrophages may 
also arise from other monocyte subsets or from locally differentiated tissue resident 
adventitial macrophages. Other monocyte subsets such as SatM may be involved in tissue 
healing and repair through their pro-fibrotic properties. 
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-USPIO/MRI, MPO/MRI  
-Fluorin-18 CLIO nanoparticles/ PET-CT 
-18F-FDG/ PET-CT 
-DOTATE/ PET or PET/MRI 
-Macroflor/PET or PET/MRI 





Analysis of circulating monocytes: 
-Subset distribution  
-Gene  and protein expression profiles 
Prognosis 
Modulation of macrophage  phenotype and activity 
 
-Immunotherapy : M2 macrophages, mesenchymal 
stem cells, supplementation with Tregs, low-dose IL-








Modulation of cytokine and chemokine 
pathways 
 
-Individual blockade of CXCR4/CXCL12, 
CCL2/CCR2 or CCL5/CCR5 
-Broad chemokine blockade with evasins 
-Blockade of IL1b, IL6, or TNF  
Monocytes - macrophages as biomarkers of AAA 




























Promotion of inflammation 
ECM degradation 











Resolution of inflammation 
Matrix stabilization 
Fibrosis 
M2 macrophages 
CXCR3+ macrophages 
HA-mac macrophages 
Classical 
Figure 4 
Resident macrophages 
